Electrophysiological characteristics of primary afferent fibers after systemic administration of anti-GD2 ganglioside antibody - PubMed (original) (raw)
Electrophysiological characteristics of primary afferent fibers after systemic administration of anti-GD2 ganglioside antibody
W H Xiao et al. Pain. 1997 Jan.
Abstract
An animal model showing mechanical allodynia following systemic bolus injection of a human/mouse chimeric monoclonal antibody to the GD2 ganglioside (ch14.18) has been established (e.g. pain behavior generated by a light tactile stimulus). This is of clinical relevance since ch14.18 is a promising experimental treatment for pediatric neuroblastoma. The present study examined the hypothesis that allodynic effects of the anti-GD2 antibody are mediated by actions on cutaneous nerve fibers. After determining the basal magnitude of the mechanical stimulus required to produce withdrawal, ch14.18, a murine form of the anti-GD2 antibody of IgG2a isotype (14G2a), a control murine anti-melanoma antibody of IgG2a isotype (9.2.27) or saline was injected through a previously implanted jugular cannula. The experimenter was blinded to the syringe contents. Withdrawal threshold was tested at 15 min intervals for 1 h. After administration of either ch14.18 or 14G2a mechanical allodynia typically started within the first 15 min and persisted throughout the hour of behavioral testing. In the control antibody group, a modest change in tactile withdrawal threshold was observed at the 60 min time point only. Rats were then anesthetized with pentobarbital and prepared for single fiber recordings from the sural nerve. Fibers were classified based on conduction velocity, as A beta (> 25 m/s), A delta (2-25 m/s) or C (< 2 m/s). Background activity (BA) was observed in a significant number of A delta (12/61) and C (32/42) fibers in both anti-GD2 treated groups compared to the anti-melanoma antibody (1/17 A delta and 2/10 C fibers) and saline (0/26 A delta and 0/19 C fibers) treated groups. Mean mechanical threshold for A delta fibers in all three antibody treated groups was significantly reduced compared to the saline control; this was not observed for C-fibers in any group. Intravenous bolus injection (15 mg/kg) and infusion of lidocaine (plasma level 0.3-2.2 micrograms/ml) both reduced anti-GD2 associated BA. These data demonstrate that mechanical-allodynia could be produced by action(s) of the anti-GD2 antibody (direct or indirect) on peripheral nerves and suggest intravenous lidocaine as part of the analgesic regimen accompanying anti-GD2 antibody treatment.
Similar articles
- An animal model of pain produced by systemic administration of an immunotherapeutic anti-ganglioside antibody.
Slart R, Yu AL, Yaksh TL, Sorkin LS. Slart R, et al. Pain. 1997 Jan;69(1-2):119-25. doi: 10.1016/s0304-3959(96)03247-2. Pain. 1997. PMID: 9060021 - Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia.
Terme M, Dorvillius M, Cochonneau D, Chaumette T, Xiao W, Diccianni MB, Barbet J, Yu AL, Paris F, Sorkin LS, Birklé S. Terme M, et al. PLoS One. 2014 Feb 10;9(2):e87210. doi: 10.1371/journal.pone.0087210. eCollection 2014. PLoS One. 2014. PMID: 24520328 Free PMC article. - Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K, Bernhardt B, Strickland B. Parsons K, et al. Ann Pharmacother. 2013 Feb;47(2):210-8. doi: 10.1345/aph.1R353. Epub 2013 Feb 5. Ann Pharmacother. 2013. PMID: 23386066 Review. - Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy.
Ahmed M, Cheung NK. Ahmed M, et al. FEBS Lett. 2014 Jan 21;588(2):288-97. doi: 10.1016/j.febslet.2013.11.030. Epub 2013 Dec 1. FEBS Lett. 2014. PMID: 24295643 Review.
Cited by
- Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effects.
Mora J, Climent A, Roldán M, Flores MC, Varo A, Perez-Jaume S, Jou C, Celma MS, Lazaro JJ, Cheung I, Castañeda A, Gorostegui M, Rodriguez E, Chamorro S, Muñoz JP, Cheung NK. Mora J, et al. Front Oncol. 2024 May 15;14:1380917. doi: 10.3389/fonc.2024.1380917. eCollection 2024. Front Oncol. 2024. PMID: 38812778 Free PMC article. - GD2-targeting therapy: a comparative analysis of approaches and promising directions.
Philippova J, Shevchenko J, Sennikov S. Philippova J, et al. Front Immunol. 2024 Mar 15;15:1371345. doi: 10.3389/fimmu.2024.1371345. eCollection 2024. Front Immunol. 2024. PMID: 38558810 Free PMC article. Review. - Development of minimally invasive cancer immunotherapy using anti-disialoganglioside GD2 antibody-producing mesenchymal stem cells for a neuroblastoma mouse model.
Kambe K, Iguchi M, Higashi M, Yagyu S, Fumino S, Kishida T, Mazda O, Tajiri T. Kambe K, et al. Pediatr Surg Int. 2022 Dec 9;39(1):43. doi: 10.1007/s00383-022-05310-z. Pediatr Surg Int. 2022. PMID: 36484857 - Sex-Specific B Cell and Anti-Myelin Autoantibody Response After Peripheral Nerve Injury.
Lee HJ, Remacle AG, Hullugundi SK, Dolkas J, Leung JB, Chernov AV, Yaksh TL, Strongin AY, Shubayev VI. Lee HJ, et al. Front Cell Neurosci. 2022 Apr 14;16:835800. doi: 10.3389/fncel.2022.835800. eCollection 2022. Front Cell Neurosci. 2022. PMID: 35496906 Free PMC article. - Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials.
Wieczorek A, Manzitti C, Garaventa A, Gray J, Papadakis V, Valteau-Couanet D, Zachwieja K, Poetschger U, Pribill I, Fiedler S, Ladenstein R, Lode HN. Wieczorek A, et al. Cancers (Basel). 2022 Apr 10;14(8):1919. doi: 10.3390/cancers14081919. Cancers (Basel). 2022. PMID: 35454826 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources